GlobeNewswire by notified

CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR

Share

ROBIT PLC          PRESS RELEASE          21 FEBRUARY 2024 AT 9.15 EET

CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR

Market demand weakened during 2023, which affected the construction industry in Europe and Asia in particular. Customer demand in the mining industry remained at a good level during the year, but the high stock levels of customers and distributors, and de-stocking, weakened Robit’s sales also in the mining industry.

Robit’s net sales for 2023 declined by 17.0 percent to EUR 92.9 million (112.0). In constant currencies, the decline was 13.7 percent. A significant reason for the decreased sales was the closure of the Russian business, which had an 8.3 percent impact on the declined net sales. The company’s full-year EBITDA decreased from the 2022 level totaling EUR 5.0 million (8.9). Profitability was weak, especially in the early part of the year, but the company managed to improve it with the help of the austerity measures implemented during the year.

In the last quarter of the year, the company’s net sales were EUR 22.9 million (26.2). Robit’s net sales increased clearly in the Australasia region, where the company won several new customers during the year.  Of the business units, Geotechnical experienced growth in the last quarter of the year, when a major project delivery was carried out to North America. Comparable EBITDA for the review period improved clearly over the comparison period to EUR 2.0 million (0.4), representing 8.6 percent of net sales (1.4).

Robit’s net cash inflow from operating activities strengthened significantly during the review period, amounting to EUR 7.0 million. The result was made possible by implementation of the Fit for Service program, which focused on strengthening cash flow. The program helped to reduce stocks in the last quarter of the year by EUR 4.3 million and during 2023 by EUR 8.3 million. The program and inventory optimisation will continue in 2024.

”The year 2023 was a year of structural changes for the company. We discontinued manufacturing at the Australian plant and centralized production to the company’s other plants to strengthen our competitiveness in the Down the Hole business. In addition, we moved all sales under the Robit brand, enabling the clarification of the organization, company structure, and product offering. In 2024, we will focus particularly on ensuring profitable growth. The company seeks growth by further strengthening the distributor network and, in the company’s direct sales countries, by focusing especially on increasing mining sales, states Arto Halonen, Group CEO.

Robit estimates that, in 2024, net sales will increase and comparable EBIT profitability in euros will improve compared to 2023.

ROBIT PLC
Arto Halonen

Further information:
Arto Halonen, Group CEO
+358 40 028 0717
arto.halonen@robitgroup.com

Distribution:
Nasdaq Helsinki Ltd
Key media
www.robitgroup.com

Robit is a strongly international growth company servicing global customers and selling drilling consumables for applications in mining, construction, geotechnical engineering and well drilling. The company’s offering is divided into three product and service ranges: Top Hammer, Down the Hole and Geotechnical. Robit has sales and service points in seven countries as well as an active sales network in more than 100 countries. Robit’s manufacturing units are located in Finland, South Korea and the UK. Robit’s share is listed on Nasdaq Helsinki Ltd. Further information is available at www.robitgroup.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and

Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release

Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat

Dr. Sam Barrell CBE appointed as CEO of LifeArc19.4.2024 17:00:00 CEST | Press release

PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam’s appointment follows an extensive international recruitment process. Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul Nurse. She joined the Crick in 2017 as Chief Operating Officer. Sam brings over 25 years of experience in the life science and healthcare sectors, and a wealth of knowledge of the activities in commercial, digital and health tech spaces which are critical to LifeArc’s strategy. She studied medicine, training as an anaesthetist and serving in General Practice for many years, and has held a number of senior leadership positions in the NHS, most recently as CEO of Taunton and Somerset NHS Foundation Trust. She

HiddenA line styled icon from Orion Icon Library.Eye